绝对立体化学对伊曲康唑抗血管生成和抗真菌活性的影响。
Impact of Absolute Stereochemistry on the Antiangiogenic and Antifungal Activities of Itraconazole.
作者信息
Shi Wei, Nacev Benjamin A, Bhat Shridhar, Liu Jun O
机构信息
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
出版信息
ACS Med Chem Lett. 2010;1(4):155-159. doi: 10.1021/ml1000068.
Abstract
Itraconazole is used clinically as an antifungal agent and has recently been shown to possess antiangiogenic acitivity. Itraconazole has three chiral centers that give rise to eight stereoisomers. The complete role of stereochemistry in the two activities of itraconazole, however, has not been addressed adequately. For the first time, all eight stereoisomers of itraconazole (1a-1h) have been synthesized and evaluated for activity against human endothelial cell proliferation and for antifungal activity against five fungal strains. Distinct antiangiogenic and antifungal activity profiles of the trans- stereoisomers, especially 1e and 1f, suggest different molecular mechanisms underlying the anti-angiogenic and anti-fungal activities of itraconazole.
摘要
伊曲康唑在临床上用作抗真菌剂，最近已被证明具有抗血管生成活性。伊曲康唑有三个手性中心，可产生八种立体异构体。然而，立体化学在伊曲康唑这两种活性中的完整作用尚未得到充分探讨。首次合成了伊曲康唑的所有八种立体异构体（1a - 1h），并评估了它们对人内皮细胞增殖的活性以及对五种真菌菌株的抗真菌活性。反式立体异构体，特别是1e和1f，具有明显不同的抗血管生成和抗真菌活性谱，这表明伊曲康唑的抗血管生成和抗真菌活性背后存在不同的分子机制。
相似文献
1
Impact of Absolute Stereochemistry on the Antiangiogenic and Antifungal Activities of Itraconazole.
ACS Med Chem Lett. 2010;1(4):155-159. doi: 10.1021/ml1000068.
2
Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole.
Clin Cancer Res. 2016 Jun 1;22(11):2709-20. doi: 10.1158/1078-0432.CCR-15-1888. Epub 2016 Jan 22.
3
Analytical and semipreparative chiral separation of cis-itraconazole on cellulose stationary phases by high-performance liquid chromatography.
J Sep Sci. 2016 Jul;39(14):2736-45. doi: 10.1002/jssc.201600240. Epub 2016 Jun 28.
4
Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.
J Med Chem. 2011 Oct 27;54(20):7363-74. doi: 10.1021/jm200944b. Epub 2011 Oct 5.
5
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
Cancer Res. 2011 Nov 1;71(21):6764-72. doi: 10.1158/0008-5472.CAN-11-0691. Epub 2011 Sep 6.
6
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
J Med Chem. 2016 Apr 28;59(8):3635-49. doi: 10.1021/acs.jmedchem.5b01718. Epub 2016 Apr 6.
7
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.
J Biol Chem. 2011 Dec 23;286(51):44045-44056. doi: 10.1074/jbc.M111.278754. Epub 2011 Oct 24.
8
Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7276-85. doi: 10.1073/pnas.1512867112. Epub 2015 Dec 10.
9
Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.
Indian J Ophthalmol. 2022 Dec;70(12):4270-4283. doi: 10.4103/ijo.IJO_855_22.
10
Investigating the susceptibility profiles and in vitro combinations of caspofungin, itraconazole, fluconazole, voriconazole, clotrimazole, and amphotericin B against clinical isolates causing fungal keratitis.
Diagn Microbiol Infect Dis. 2025 Jul;112(3):116806. doi: 10.1016/j.diagmicrobio.2025.116806. Epub 2025 Mar 15.
引用本文的文献
1
Discovery of semisynthetic derivatives of ()- and ()-usnic acids as potential antifungal agents against and .
RSC Med Chem. 2025 Jul 10. doi: 10.1039/d5md00457h.
2
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer.
Front Pharmacol. 2022 Jun 3;13:869461. doi: 10.3389/fphar.2022.869461. eCollection 2022.
3
Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors.
ACS Med Chem Lett. 2020 Apr 8;11(6):1111-1117. doi: 10.1021/acsmedchemlett.9b00438. eCollection 2020 Jun 11.
4
Structural basis for itraconazole-mediated NPC1 inhibition.
Nat Commun. 2020 Jan 9;11(1):152. doi: 10.1038/s41467-019-13917-5.
5
Inhibitors of Brassinosteroid Biosynthesis and Signal Transduction.
Molecules. 2019 Nov 29;24(23):4372. doi: 10.3390/molecules24234372.
6
Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
J Med Chem. 2019 Apr 25;62(8):3873-3885. doi: 10.1021/acs.jmedchem.8b01283. Epub 2019 Apr 5.
7
Intravitreal itraconazole inhibits laser-induced choroidal neovascularization in rats.
PLoS One. 2017 Jun 30;12(6):e0180482. doi: 10.1371/journal.pone.0180482. eCollection 2017.
8
Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling.
J Vis Exp. 2016 Sep 20(115):54529. doi: 10.3791/54529.
9
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
J Med Chem. 2016 Apr 28;59(8):3635-49. doi: 10.1021/acs.jmedchem.5b01718. Epub 2016 Apr 6.
10
Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7276-85. doi: 10.1073/pnas.1512867112. Epub 2015 Dec 10.
本文引用的文献
1
Cholesterol trafficking is required for mTOR activation in endothelial cells.
Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4764-9. doi: 10.1073/pnas.0910872107. Epub 2010 Feb 22.
2
Inhibition of angiogenesis by the antifungal drug itraconazole.
ACS Chem Biol. 2007 Apr 24;2(4):263-70. doi: 10.1021/cb600362d.
3
Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists.
J Med Chem. 2006 Oct 19;49(21):6351-63. doi: 10.1021/jm060262x.
4
Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles.
Toxicology. 2006 Nov 10;228(1):24-32. doi: 10.1016/j.tox.2006.08.007. Epub 2006 Aug 12.
5
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
J Med Chem. 2006 Apr 20;49(8):2512-25. doi: 10.1021/jm051211n.
6
Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Drug Metab Dispos. 2006 Apr;34(4):583-90. doi: 10.1124/dmd.105.008508. Epub 2006 Jan 13.
7
Molecular design of two sterol 14alpha-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole.
J Comput Aided Mol Des. 2005 Mar;19(3):149-63. doi: 10.1007/s10822-005-3692-7.
8
Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors.
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3068-73. doi: 10.1073/pnas.061562898.
9
Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents.
Yeast. 1999 Jun 30;15(9):755-63. doi: 10.1002/(SICI)1097-0061(19990630)15:9<755::AID-YEA417>3.0.CO;2-8.
10
Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones.
J Med Chem. 1984 Jul;27(7):894-900. doi: 10.1021/jm00373a015.
Zotero 插件